Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-11-02 00:00:00 ET · period of report 2023-11-01 · accession 0001883850-23-000079 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-11-02 | 2023-11-01 | REGN | McCourt Marion | EVP Commercial | M - OptEx | $381.40 | +1,000 | 20.8K | +5% | +$381.4K |
| D | 2023-11-02 | 2023-11-01 | REGN | McCourt Marion | EVP Commercial | S - Sale+OE | $783.91 | -1,000 | 19.8K | -5% | -$783.9K |
| D | 2023-11-02 | 2023-11-01 | REGN | McCourt Marion | EVP Commercial | M - OptEx | $0.00 | -1,000 | 9,000 | -10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-01 | M | A | 1,000 | $381.40 | 20,803 | D | — | — | |
| 2 | Common | Common Stock | 2023-11-01 | S | D | 1,000 | $783.91 | 19,803 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-11-01 | M | D | 1,000 | $0.00 | 9,000 | D | $381.40 · — to 2028-12-12 | 1,000 Common Stock | (F2) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |